Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The promise of in silico drug development to improve patient outcomes

Tanja Dowe
Meds
July 2, 2022
Share
Tweet
Share

In the last two years, pharmaceutical companies have become increasingly interested in the possibilities in silico technologies bring to the world’s multi-billion-dollar drug development market. Among the factors that have been reported as drivers of recent interest in what is also known as virtual clinical trials are the COVID-19-related restrictions that began impacting traditional human-based clinical trials in 2020.

In silico drug development utilizes real-world data (RWD), artificial intelligence (AI), computational biology, and mechanistic modeling to predict the efficacy and safety of drug treatments or to simulate control arms in clinical trials. By reducing the risk of failure or the size of control arms, in silico drug development is cost-effective and promises to create safer, more efficient drug development, reducing the time it takes to bring a drug to market. Although it represents only a small fraction of the annual global spend on drug development, the value of the in silico drug development market is expected to reach nearly $3 billion by the end of 2022.

Also, most importantly, by accelerating research and development (R&D) timelines, in silico drug development has the potential to bring better outcomes to patients faster.

With the goal of reducing R&D costs and time-to-market of novel therapies, some companies perform in silico simulation in different stages of drug development for pharma and biotech companies throughout the world. In silico simulation reduces R&D decision-related risks by predicting the clinical benefits of new drugs before a human trial is conducted and helps identify ineffective therapies at an early stage, or partly replaces and complements costly clinical study control arms, saving drug developers time and money.

U.S. regulators weigh in on reduced animal testing

Regulatory agencies also recognize the value of the virtual clinical trial model and regulators are expected to endorse an increasing range of therapies that begin their development journey in an in silico trial. In its report entitled 2021 Advancing Regulatory Science at FDA: Focus Areas of Regulatory Science, the U.S. Food and Drug Administration stated that the emergence of in silico trials has the potential to “replace, reduce, and refine reliance on animal testing.”

According to the report, “In some cases, in silico modelings such as using available information in computational science approaches to predict safety issues, can be used to supplement and may potentially replace risk analyses that are currently based on animal data.” By relying less on animal testing, pharma and biotech companies will have the advantage of utilizing more human-based data in the development of novel therapies.

Giving patients access to personalized medicine

In silico technologies also enable drug developers to perform, in theory, an unlimited number of tests using a wide range of variables that include age, sex, and the health status of each member of the virtual patient pool, compared to the more restrictive parameters of a traditional trial. By reducing the amount of trial and error involved in collecting data, drug developers can focus on therapies that prove to be more effective in treating a specific group of patients.

This increase of data related to the way a drug impacts specific patient populations will also help drive the development of personalized medicine. By performing in silico studies, drug makers will have the opportunity to develop better-targeted therapies for patients with critical diseases such as cancer, through the benefit of data that provides a deeper look at how each patient reacts to a treatment.

As the prevalence of in silico drug development increases in the years ahead, the pharmaceutical and biotech community is optimistic that more effective and affordable treatments will become available to the people who need them, and positive patient outcomes will rise dramatically.

Tanja Dowe is a health care executive. 

Image credit: Shutterstock.com

Prev

5 tips for treating high-weight patients

July 2, 2022 Kevin 0
…
Next

When the music stopped

July 2, 2022 Kevin 0
…

Tagged as: Medications

Post navigation

< Previous Post
5 tips for treating high-weight patients
Next Post >
When the music stopped

Related Posts

  • 3 medical student tips to improve patient communication

    Subha Mohan
  • How value-based pay can worsen patient outcomes

    Matthew Hahn, MD
  • Do quality metrics really improve patient care?

    Fred N. Pelzman, MD
  • Physicians and patients must work together to improve health care

    Michele Luckenbaugh
  • A universal patient medical record

    Michael R. McGuire
  • A patient waits. And waits.

    Michele Luckenbaugh

More in Meds

  • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

    Julie Craig, MD
  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Most Popular

  • Past Week

    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond pizza and pens: National Doctors’ Day should be about saving lives

      James Young, MD | Physician
    • Physicians are a finite resource we need to protect

      Jack Resneck, Jr., MD | Physician
    • From clocking in to clocking out: the transition to retirement

      Debbie Moore-Black, RN | Conditions
    • From license to loneliness: the dilemma of retired physicians

      Richard Plotzker, MD | Physician
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
  • Recent Posts

    • From license to loneliness: the dilemma of retired physicians

      Richard Plotzker, MD | Physician
    • Tackling the health care crisis with artificial intelligence: Combating physician and nursing shortages in the United States

      Harvey Castro, MD, MBA | Tech
    • From hope to heartbreak: a story of loss in the ICU

      Ton La, Jr., MD, JD | Conditions
    • Unlearning our habits: a journey from intelligence to wisdom

      Brian Sayers, MD | Physician
    • Lessons from an orthopedic surgery journey [PODCAST]

      The Podcast by KevinMD | Podcast
    • Beyond pizza and pens: National Doctors’ Day should be about saving lives

      James Young, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Want to Fix Medicare Pay for Primary Care Docs? How About Two Fee Schedules?
  • OTC Narcan Approval Opens New Doors in Fight Against Opioid Crisis
  • U.S. 'Flying Blind' When It Comes to Data on Substance Use in Pregnancy
  • Fear of Family Separation a Barrier to Addiction Care During Pregnancy
  • Mothers Face Broken Addiction Treatment System

Meeting Coverage

  • VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy
  • Obesity's Impact on Uterine Cancer Risk Greater in Younger Age Groups
  • Oral Roflumilast Effective in the Treatment of Plaque Psoriasis
  • Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer
  • Cannabis Use Common in Post-Surgery Patients on Opioid Tapering
  • Most Popular

  • Past Week

    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond pizza and pens: National Doctors’ Day should be about saving lives

      James Young, MD | Physician
    • Physicians are a finite resource we need to protect

      Jack Resneck, Jr., MD | Physician
    • From clocking in to clocking out: the transition to retirement

      Debbie Moore-Black, RN | Conditions
    • From license to loneliness: the dilemma of retired physicians

      Richard Plotzker, MD | Physician
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
  • Recent Posts

    • From license to loneliness: the dilemma of retired physicians

      Richard Plotzker, MD | Physician
    • Tackling the health care crisis with artificial intelligence: Combating physician and nursing shortages in the United States

      Harvey Castro, MD, MBA | Tech
    • From hope to heartbreak: a story of loss in the ICU

      Ton La, Jr., MD, JD | Conditions
    • Unlearning our habits: a journey from intelligence to wisdom

      Brian Sayers, MD | Physician
    • Lessons from an orthopedic surgery journey [PODCAST]

      The Podcast by KevinMD | Podcast
    • Beyond pizza and pens: National Doctors’ Day should be about saving lives

      James Young, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...